Терапевтически индуцированная нейроэндокринная дифференцировка рака предстательной железы

Терапевтически индуцированная нейроэндокринная дифференцировка рака предстательной железы

Автор: Ковченко Г.А., Сивков А.В., Ефремов Г.Д., Каприн А.Д.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Онкоурология

Статья в выпуске: 3 т.17, 2024 года.

Бесплатный доступ

Введение. Применение селективных высокоэффективных антиандрогенных препаратов при кастрационно-резистентном раке предстательной железы (КРРПЖ) постепенно ведет к клеточной трансформации. Цель работы: изучить современные представления о распространенности нейроэндокринной дифференцировки (НЭД) у больных КРРПЖ, а также лечение данного агрессивного варианта РПЖ.

Терапевтически индуцированная нейроэндокринная дифференцировка рака предстательной железы, резистентность рецепторов андрогенов к терапии рпж, лечение нейроэндокринного рака предстательной железы

Короткий адрес: https://sciup.org/142243276

IDR: 142243276   |   DOI: 10.29188/2222-8543-2024-17-3-62-67

Список литературы Терапевтически индуцированная нейроэндокринная дифференцировка рака предстательной железы

  • Носов Д.А., Волкова М.И., Гладков О.А., Карабина Е.В., Крылов В.В., Матвеев В.Б., Митин Т., Попов А.М. Практические рекомендации по лечению рака предстательной железы. Злокачественные опухоли 2022;12(3S2-1):607-26. [Nosov D.A., Volkova M.I., Gladkov O.A., Karabina E.V., Krylov V.V., Matveev V.B., Mitin T., Popov A.M. Practical recommendations for the treatment of prostate cancer. Zlokachestvennyye opukholi = Malignant Tumoursis 2022;12(3S2-1):607-26. (In Russian)]. https://doi.org/10.18027/2224-5057-2022-12-3s2-607-626.
  • Каприн А.Д., Алексеев Б.Я., Матвеев В.Б. и др. Клинические рекомендации: Рак предстательной железы 2021:1-175. [Kaprin A.D., Alekseev B.Ya., Matveev V.B. et al. Clinical guidelines: Prostate cancer 2021:1-175. (In Russian)].
  • Vellky JE, Ricke WA. Development and prevalence of castration-resistant prostate cancer subtypes. Neoplasia 2020;22(11):566-75. https://doi.org/10.1016/j.neo.2020.09.002.
  • Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006;12(6):1665-71. https://doi.org/10.1158/1078-0432.CCR-06-0067.
  • Ковченко Г.А., Сивков А.В., Каприн А.Д. Роль определения хромогранина А в лечении больных кастрационно-резистентным раком предстательной железы. Экспериментальная и клиническая урология 2024;17(1):75-85. [Kovchenko G.A., Sivkov A.V., Kaprin A.D. The role of chromogranin A determination in the treatment of patients with cas-tration-resistant prostate cancer. Eksperimental'naya i klinicheskaya urologiya = Experimental and Clinical Urology 2024;17(1):75-85. (In Russian)]. https://doi.org/10.29188/2222-8543-2024-17-1-75-85.
  • Niu Y, Guo C, Wen S, Tian J, Luo J, Wang K, et al. ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis. Cancer Lett 2018;439:47-55. https://doi.org/10.1016/j.canlet.2018.09.020.
  • Wang HT, Yao YH, Li BG, Tang Y, Chang JW, Zhang J. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosisa systematic review and pooled analysis. J Clin Oncol 2014;32(30):3383-90. https://doi.org/10.1200/JCO.2013.54.3553.
  • Beltran H, et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res 2019;25:6916-24. https://doi.org/10.1158/1078-0432.CCR-18-1912.
  • Chen R, Dong X, Gleave M. Molecular model for neuroendocrine prostate cancer progression. BJU Int 2018;122:560-70. https://doi.org/10.1111/bju.14207.
  • Kench JG, Amin MB, Berney DM, Compérat EM, Cree IA, Gill AJ, et al. WHO Classification of tumours fifth edition: evolving issues in the classification, diagnosis, and prognosti-cation of prostate cancer. Histopathology 2022;81(4):447-58. https://doi.org/10.1111/his.14711.
  • Сивков А.В., Кешишев Н.Г., Ефремов Г.Д., Ковченко Г.А., Рабинович Э.З., Трудов А.А., и соавт. Нейроэндокринная дифференцировка рака предстательной железы, что нового? Экспериментальная и клиническая урология 2015;(3):22-30. [Sivkov A.V., Keshishev N.G., Efremov G.D., Kovchenko G.A., Rabinovich E.Z., Trudov A.A., et al. Neuroendocrine differentiation of prostate cancer, what's new? Eksperimental'naya i klinicheskaya urologiya = Experimental and Clinical Urology 2015;(3):22-30. (In Russian)].
  • Xie Y, Ning S, Hu J. Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression. J Cancer Res Clin Oncol 2022;148(7):1813-23. https://doi.org/10.1007/s00432-022-04061-7.
  • Puca L, Vlachostergios PJ, Beltran H. Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies. Cold Spring Harb Perspect Med 2019;9(2):a030593. https://doi.org/10.1101/cshperspect.a030593.
  • Zamora I, Freeman MR, Encío IJ, Rotinen M. Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer. Int J Mol Sci 2023;24(18):13673. https://doi.org/10.3390/ijms241813673.
  • Wishahi M. Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factors. World J Clin Cases 2024;12(13):2143-6. https://doi.org/10.12998/wjcc.v12.i13.2143.
  • Long Z, Deng L, Li C, He Q, He Y, Hu X, et al. Loss of EHF facilitates the development of treatment-induced neuroendocrine prostate cancer. Cell Death Dis 2021;12(1):46. https://doi.org/10.1038/s41419-020-03326-8.
  • Dhavale M, Abdelaal MK, Alam ABMN, Blazin T, Mohammed LM, Prajapati D, et al. Androgen receptor signaling and the emergence of lethal neuroendocrine prostate cancer with the treatment-induced suppression of the androgen receptor: a literature review. Cureus 2021;13(2):e13402. https://doi.org/10.7759/cureus.13402.
  • Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, et al. Clinical features of neu-roendocrine prostate cancer. Eur J Cancer 2019;121:7-18. https://doi.org/10.1016/j.ejca.2019.08.011.
  • Akoto T, Bhagirath D, Saini S. MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer. Cancer Drug Resist 2020;3(4):804-18. https://doi.org/10.20517/cdr.2020.30.
  • Patel GK, Chugh N, Tripathi M. Neuroendocrine differentiation of prostate canceran intriguing example of tumor evolution at play. Cancers (Basel) 2019;11. https://doi.org/10.3390/cancers11101405.
  • Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study. J Clin Oncol 2018;36(24):2492-503. https://doi.org/10.1200/JCO.2017.77.6880.
  • Fine SW. Neuroendocrine tumors of the prostate. Mod Pathol 2018;31(S1):S122S132. https://doi.org/10.1038/modpathol.2017.164.
  • Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalu-tamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424-33. https://doi.org/10.1056/NEJMoa1405095.
  • Kaarijärvi R, Kaljunen H, Ketola K. Molecular and Functional Links between Neurodevel-opmental Processes and Treatment-Induced Neuroendocrine Plasticity in Prostate Cancer Progression. Cancers (Basel) 2021;13(4):692. https://doi.org/10.3390/cancers13040692.
  • Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA 2019;116(23):11428-36. https://doi.org/10.1073/pnas.1902651116.
  • Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, et al. SOX2 promotes line-age plasticity and antiandrogen resistance in TP53and RB1-deficient prostate cancer. Science 2017;355(6320):84-8. https://doi.org/10.1126/science.aah4307.
  • Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017;23(8):1004. https://doi.org/10.1038/nm0817-1004c.
  • Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011;1:487. https://doi.org/10.1158/2159-8290.
  • Zou M, Toivanen R, Mitrofanova A, Floch N, Hayati S, Sun Y, et al. Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer. Cancer Discov 2017;7(7):736-49. https://doi.org/10.1158/2159-8290.CD-16-1174.
  • Zhang XQ, Kondrikov D, Yuan TC, Lin FF, Hansen J, Lin MF. Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene 2003;22(43):6704-16. https://doi.org/10.1038/sj.onc.1206764.
  • Weng XT, Lin WL, Pan QM, Chen TF, Li SY, Gu CM. Aggressive variant prostate cancer: A case report and literature review. World J Clin Cases 2023;11(26):6213-22. https://doi.org/10.12998/wjcc.v11.i26.6213.
  • Schaeffer EM, Srinivas S, Adra N, Barocas D, Bitting R, Bryce A, et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2023;21(10):1067-96. https://doi.org/10.6004/jnccn.2023.0050.
  • Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 2024;86(2):164-82. https://doi.org/10.1016/j.eururo.2024.04.010.
  • Носов Д.А., Волкова М.И., Гладков О.А., Карабина Е.В., Крылов В.В., Матвеев В.Б. и соавт. Практические рекомендации по лечению рака предстательной железы. Злокачественные опухоли 2022;12(3S2):607-26. [Nosov D.A., Volkova M.I., Gladkov O.A., Karabina E.V., Krylov V.V., Matveev V.B. et al. Practical recommendations for the treatment of prostate cancer. Zlokachestvennyye opukholi = Malignant Tumors 2022;12(3S2):607-26. (In Russian)]. https://doi.org/10.18027/2224-5057-2022-12-3s2-607-626.
  • Yamada Y, Beltran H. Clinical and Biological Features of Neuroendocrine Prostate Cancer. Curr Oncol Rep 2021;23(2):15. https://doi.org/10.1007/s11912-020-01003-9.
  • Алексеев Б.Я., Каприн А.Д., Нюшко К.М. Роль аналогов соматостатина в лечении больных гормонорефрактерным раком предстательной железы. Онкоурология 2011;(2):84-8. [Alekseev B.Y., Kaprin A.D., Nyushko K.M. The role of somatostatin analogues in the treatment of patients with hormone-refractory prostate cancer. Onkourologiya = Cancer Urology 2011;(2):84-8. (In Russian)].
  • Mitsiades CS, Bogdanos J, Karamanolakis D, Milathianakis C, Dimopoulos T, Koutsilieris M. Randomized controlled clinical trial of a combination of somatostatin analog and dexa-methasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Res 2006;26(5B):3693-700.
  • Ge R, Wang Z, Montironi R, Jiang Z, Cheng M, Santoni M, et al. Epigenetic modulations and lineage plasticity in advanced prostate cancer. Ann Oncol 2020;31(4):470-9. https://doi.org/10.1016/j.annonc.2020.02.002.
Еще
Статья обзорная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp